Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,050 recruiting studies in this area right now.
By phase
- Not applicable2,999
- Phase 21,056
- Phase 1792
- Phase 1/Phase 2437
- Phase 3435
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes130
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland199
- Alabama178
- Florida149
- Arizona148
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,050 total
- NCT07452198RecruitingPhase 3
Study of new drug for relapsed or hard-to-treat multiple myeloma
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
TianjinAges 18 years+ - NCT07445919RecruitingPhase 2
Testing SM17 for moderate-to-severe eczema
This trial tests an investigational drug called SM17 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if SM17 can reduce itching and skin symptoms when topical treatments haven't worked well enough.
BeijingAges 18–70 - NCT04929899Recruiting
Test of a learning tool during leukemia maintenance
This study checks whether a tablet-based tool (called PeNAT) can be used by children during the usual maintenance treatment phase for ALL (a type of leukemia). It may help families and clinicians better support care at home or during follow-up by testing how well the tool works in real patients.
Los Angeles, CaliforniaAges 4–18 - NCT06803758Recruiting
Testing teicoplanin allergy with your own blood
This study tests a new way to check if you are allergic to the antibiotic teicoplanin using your own blood serum. It aims to help doctors know for sure if you had a severe allergic reaction during a past surgery.
SouthamptonAges 18 years+ - NCT06804694Recruiting
Technology-based support for young adults with type 1 diabetes distress
This study tests a special program that combines technology and a care team to help young adults with type 1 diabetes who feel stressed or overwhelmed by their diabetes. The goal is to see if this approach is helpful and manageable for participants.
Toronto, OntarioAges 18–29 - NCT06805448RecruitingPhase 1/Phase 2
Stem cell treatment for dry mouth in Sjögren's disease
This trial tests if injecting fat-derived stem cells into the salivary glands can help relieve dry mouth in people with Sjögren's disease. It aims to improve saliva flow and reduce discomfort.
CopenhagenAges 18 years+ - NCT04320680Recruiting
Study visits for adults with lupus in Brest, France
This study focuses on people aged 18 and older with lupus who attend a multi-team clinic visit in Brest, France. It mainly looks at whether you can participate in the multidisciplinary consultation and its related study procedures.
BrestAges 18–80 - NCT05349006RecruitingPhase 3
Azathioprine for first attack in MOG antibody disease
This Phase 3 trial studies whether azathioprine can help prevent problems after a first attack of MOG antibody–related inflammation of the brain/spinal cord. It’s for adults with a recent first episode and confirmed MOG antibodies.
BordeauxAges 18 years+ - NCT06668792RecruitingPhase 2
Study of BCD-248 for returning multiple myeloma
This trial tests a new treatment called BCD-248 for people whose multiple myeloma has come back or stopped responding to at least two prior treatments. It aims to see if it is safe and effective.
KaliningradAges 18 years+ - NCT06806488Recruiting
Marginal zone lymphoma patient study
This study looks at patients with marginal zone lymphoma who were diagnosed and treated at a specific hospital in Italy between 2012 and 2018. It aims to learn more about how the disease progresses and how patients respond to treatment.
Bologna, BolognaAges 18 years+ - NCT06807736Recruiting
Choosing injectable PrEP for HIV prevention in Cape Town
This study offers three ways to prevent HIV: a shot every two months (injectable PrEP), daily pills, or a vaginal ring. Researchers in Cape Town will help you choose the option that fits your life best.
Cape Town, Western ProvinceAges 15 years+ - NCT07444567RecruitingPhase 3
Continuing benralizumab treatment after a previous study
This trial lets people who completed an earlier benralizumab study and are benefiting from the medicine keep receiving it. The goal is to provide ongoing access while we continue to monitor safety and effectiveness.
Aurora, ColoradoAges 6 years+ - NCT07444307RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses specially designed immune cells to target and destroy cells causing the disease.
Hefei, AnhuiAges 18–65 - NCT07439653RecruitingPhase 1/Phase 2
Testing TORL-5-700 for advanced lymphoma
This trial tests a new treatment called TORL-5-700 for people with certain types of non-Hodgkin lymphoma that have not responded to other treatments. The goal is to see how safe it is and how well it works.
Fullerton, CaliforniaAges 18 years+ - NCT07444008Recruiting
BioAmicus Complete for infant digestive and skin issues
This study tests if BioAmicus Complete, a probiotic blend, can help babies with colic, reflux, diarrhea or constipation, and food allergy-related skin problems. Eligible babies are 1 to 4.5 months old, breastfed or formula-fed, and whose parents speak Russian.
Saint PetersburgAges 1 month–5 months - NCT07435779RecruitingEarly Phase 1
CAR-T cell therapy for severe ulcerative colitis
This trial tests a new treatment using your own immune cells (called CAR-T cells) to calm down the immune attack that causes ulcerative colitis. It is for people with moderate to severe colitis who have not gotten better with standard medicines.
GuangzhouAges 18–60 - NCT07444489Enrolling by invitationPhase 3
Long-term safety of felzartamab for kidney transplant rejection
This study checks the long-term safety of felzartamab for people who have had a kidney transplant and are dealing with antibody-mediated rejection or signs of inflammation in the kidney. It's for those who were already in a previous study and took at least one dose of felzartamab.
Los Angeles, CaliforniaAges 18–75 - NCT07441395RecruitingPhase 2
Study of soquelitinib for moderate to severe eczema
This trial tests an experimental pill called soquelitinib for people with moderate to severe eczema (atopic dermatitis). It aims to see if the drug can reduce symptoms like itching and skin inflammation.
South San Francisco, CaliforniaAges 18 years+ - NCT07438496RecruitingPhase 3
Study of nipocalimab for moderate to severe lupus
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
Beverly Hills, CaliforniaAges 18–75 - NCT07438405RecruitingPhase 2
Long-term safety study of AMG 732 for thyroid eye disease
This trial tests the long-term safety and effectiveness of AMG 732 for people with moderate-to-severe thyroid eye disease who have already completed an Amgen study of this drug. It allows continued treatment without needing immediate eye surgery.
Little Rock, ArkansasAges 18–99 - NCT06807307Recruiting
Using genetic tests to predict immunotherapy response in lung cancer
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
RomeAges 18 years+ - NCT07438067RecruitingPhase 1
EBV-targeted cell therapy after stem cell transplant
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
BeijingAges 18–75 - NCT07444632RecruitingPhase 1
Gene-modified cord blood cells for advanced blood cancers
This trial tests a new type of immune cell therapy using cord blood cells that are grown to attack cancer cells. It is for people with certain blood cancers (lymphoma or acute lymphoblastic leukemia) that have come back or not responded to standard treatments.
Houston, TexasAges 18–75 - NCT07437222Recruiting
Ginger capsules for inflammation in overweight adults
This study tests whether taking ginger capsules can help reduce inflammation, oxidative stress, and improve blood vessel function in people who are overweight or obese but otherwise healthy. You would take ginger capsules daily for several weeks and have your blood and blood vessel health checked.
Murcia, MurciaAges 23–65
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,050 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,115 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.